硼替佐米治疗滤泡性淋巴瘤疗效及不良反应的分析

Analysis of Bortezomib Treatment Efficacy and Adverse Reactions for Patients with Follicular Lymphoma

目的:研究硼替佐米治疗滤泡性淋巴瘤(FL)的临床疗效及安全性。方法:本院收治的56例FL患者,根据治疗方法分为CHOP组(26例)和硼替佐米组(30例)。CHOP组采用(环磷酰胺+表阿霉素+长春新碱+波尼松龙)治疗,硼替佐米组在CHOP方案基础上加用硼替佐米治疗。对两组患者的临床疗效及不良反应进行了比较分析。结果:硼替佐米组的近期疗效显著优于CHOP组(P<0.05),硼替佐米组总有效率80%,显著高于CHOP组的53.85%(P<0.05)。硼替佐米组的无进展生存期显著长于CHOP组(10个月vs 6个月)(P=0.013);两组的1年总生存期中位时间无统计学差异(10个月vs 11个月)(P=0.107)。两组患者的各项不良反应发生率比较差异均不显著(P>0.05)。结论:硼替佐米联合CHOP化疗可显著延长FL患者的无进展生存期,提高总有效率,且不良反应发生无明显增加;总生存期是否有益需要进一步延长随访时间观察。

Objective：This study was aimed to investigate the therapeutic efficacy and safety of bortezomib in the treatment of follicular lymphoma patients. Methods： According to treatment methods, the 56 follicular lymphoma patients were divided into 2 groups： CHOP group （26 cases） and bortezomib group （30 cases）. The patients in CHOP group received the CHOP chemotherapy regimens （ cyclophosphamide ＋ epirubicin ＋ vincdstine ＋ prednisolone ）, the patients in bortezomib group received bortezomib based on CHOP. The clinical curative effect and adverse reaction between the two groups were compared. Results： The short-term efficacy of bortezomib group showed significantly better than that in CHOP group （ P 〈 0.05 ）, the total efficiency in bortezomib group （ 80% ） was significantly higher than that in CHOP group （53.85%） （P 〈0.05）. The progression free survival of the patients in the bortezomib group was statistically longer than that in the CHOP group （ 10 months vs 6 months） （ P = 0. 013 ）. There was no significant differences in the overall survival mediam survival time between these two groups （ 10 months vs 11 months） （ P = 0. 107）. The occurrence of adverse reactions in the two groups was no significant different （P 〉 0.05）. Conclusion： Bortezomib combined with CHOP chemotherapy can obviously prolong the progression free survival of patients, and improve the total efficiency without increase of adverse reaction. The benefit to overall survival needs to further extend follow-up observation.